Story
Moderna Receives FDA Approval for First mRNA-Based Influenza Vaccine

Moderna (NASDAQ: MRNA) announced Thursday it has secured U.S. Food and Drug Administration (FDA) approval for mFLUSIVA, its influenza vaccine for adults aged 50 and older. The decision marks the first U.S. approval for an mRNA-based flu shot and represents the fourth FDA-approved product for the biotechnology company.
Approval and Availability
According to Moderna, the company expects to begin supplying the vaccine to select U.S. retailers in the coming weeks, positioning it for the 2026-2027 respiratory virus season. The approval follows a unanimous recommendation from the FDA's Vaccines and Related Biological Products Advisory Committee.
This clearance expands Moderna's portfolio to five approved products globally. For investors, it signifies a critical step in diversifying the company's revenue streams beyond its well-known COVID-19 vaccine, demonstrating the broader applicability of its mRNA technology platform.
Clinical Trial Basis
The FDA's decision was based on data from a large-scale Phase 3 trial. Key details from the clinical program include:
Ad- The study involved 40,805 adults aged 50 and older across 11 countries.
- The company reported an acceptable safety profile with no new safety concerns identified during the trial.
For adults aged 65 and older, the vaccine received accelerated approval. This was based on immune response data from a separate U.S. trial involving 2,992 participants. Moderna will be required to conduct confirmatory post-marketing studies to verify the clinical benefit in this older demographic.
Market and Global Outlook
Chief Executive Stephane Bancel stated that the approval provides an important additional vaccination option for older adults, a population at higher risk for severe outcomes from influenza. The successful application of its mRNA platform to influenza is a strategic win for the company.
Moderna is also pursuing global approvals for mFLUSIVA. The company confirmed that regulatory applications are currently under review in the European Union, Canada, and Australia, with additional filings planned for later this year.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.